Form 4: Delcath Systems Director Steven Salamon Acquires Stock Options

Director Steven Salamon acquired stock options in Delcath Systems, Inc. on May 23, 2024.

Summary

• Steven Salamon, a director of Delcath Systems, Inc., filed a Form 4 on May 28, 2024.
• The filing reports a transaction that occurred on May 23, 2024, where Salamon acquired stock options.
• Salamon acquired options to purchase 22,500 shares of Delcath Systems, Inc. common stock at an exercise price of $7.85.
• The options vest monthly over a year, starting May 23, 2024, contingent on continued service as a director.
• The options expire 10 years from the grant date or two years after the last day of service, whichever is earlier.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it can signal confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock options are a common form of compensation for directors and executives, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, often used to incentivize performance and retain key personnel.
• The vesting schedule of one-twelfth per month is a fairly typical arrangement, providing a steady stream of incentives over time.
• The ten-year expiration date is also a common feature, allowing ample time for the options to become valuable if the company performs well.

Key Dates